Which has higher earnings & valuation, EVO or ALMR?

Alamar Biosciences has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Alamar Biosciences $74.21M 32.02 -$29.82M -$1.96 N/A

Does the media refer more to EVO or ALMR?

In the previous week, Evotec had 7 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Evotec and 3 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.46 beat Evotec's score of -0.13 indicating that Alamar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, EVO or FTRE?

Evotec has higher earnings, but lower revenue than Fortrea. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Fortrea $2.68B 0.65 -$986.20M -$0.91 N/A

Is EVO or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 10.72% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Fortrea -3.18% 10.72% 2.17%

Which has higher valuation and earnings, EVO or BLFS?

BioLife Solutions has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A BioLife Solutions $96.21M 18.84 -$4.59M $1.16 31.98

Is EVO or BLFS more profitable?

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% BioLife Solutions 53.29% 2.70% 2.49%

Does the media favor EVO or BLFS?

In the previous week, Evotec had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Evotec and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.62 beat Evotec's score of -0.13 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BioLife Solutions 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, EVO or MRVI?

Evotec has higher revenue and earnings than Maravai LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Maravai LifeSciences $185.74M 12.08 -$130.77M -$0.52 N/A

Does the media prefer EVO or MRVI?

In the previous week, Evotec had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Evotec and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.19 beat Evotec's score of -0.13 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, EVO or AZTA?

Azenta has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.77 -$117.12M N/A N/A Azenta $593.82M 2.76 -$55.76M -$2.76 N/A

Is EVO or AZTA more profitable?

Azenta has a net margin of -20.63% compared to Evotec's net margin of -26.20%. Azenta's return on equity of 1.18% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Azenta -20.63% 1.18% 0.97%

Does the media favor EVO or AZTA?

In the previous week, Evotec had 8 more articles in the media than Azenta. MarketBeat recorded 10 mentions for Evotec and 2 mentions for Azenta. Azenta's average media sentiment score of 0.00 beat Evotec's score of -0.13 indicating that Azenta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Azenta 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evotec (EVO) Competitors

$1.93 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

EVO vs. ALMR, FTRE, BLFS, MRVI, and AZTA

Should you buy Evotec stock or one of its competitors? Evotec's main competitors and comparable companies include Alamar Biosciences (ALMR), Fortrea (FTRE), BioLife Solutions (BLFS), Maravai LifeSciences (MRVI), and Azenta (AZTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Evotec compare to Alamar Biosciences?

Evotec (NASDAQ:EVO) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Evotec had 7 more articles in the media than Alamar Biosciences. MarketBeat recorded 10 mentions for Evotec and 3 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.46 beat Evotec's score of -0.13 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Alamar Biosciences' return on equity of 0.00% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Alamar Biosciences	N/A	N/A	N/A

Evotec currently has a consensus price target of $3.00, suggesting a potential upside of 55.44%. Alamar Biosciences has a consensus price target of $31.80, suggesting a potential downside of 7.13%. Given Evotec's higher possible upside, equities research analysts clearly believe Evotec is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

5.8% of Evotec shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alamar Biosciences has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Alamar Biosciences	$74.21M	32.02	-$29.82M	-$1.96	N/A

Summary

Alamar Biosciences beats Evotec on 8 of the 12 factors compared between the two stocks.

How does Evotec compare to Fortrea?

Evotec (NASDAQ:EVO) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

In the previous week, Evotec had 10 more articles in the media than Fortrea. MarketBeat recorded 10 mentions for Evotec and 0 mentions for Fortrea. Fortrea's average media sentiment score of 0.00 beat Evotec's score of -0.13 indicating that Fortrea is being referred to more favorably in the news media.

Company	Overall Sentiment
Evotec	Neutral
Fortrea	Neutral

5.8% of Evotec shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evotec has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Evotec has higher earnings, but lower revenue than Fortrea.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Fortrea	$2.68B	0.65	-$986.20M	-$0.91	N/A

Evotec currently has a consensus price target of $3.00, indicating a potential upside of 55.44%. Fortrea has a consensus price target of $20.75, indicating a potential upside of 12.83%. Given Evotec's higher possible upside, equities analysts plainly believe Evotec is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Fortrea has a net margin of -3.18% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 10.72% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Fortrea	-3.18%	10.72%	2.17%

Summary

Fortrea beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Evotec compare to BioLife Solutions?

Evotec (NASDAQ:EVO) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

5.8% of Evotec shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Evotec had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Evotec and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.62 beat Evotec's score of -0.13 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioLife Solutions	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
BioLife Solutions	53.29%	2.70%	2.49%

BioLife Solutions has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
BioLife Solutions	$96.21M	18.84	-$4.59M	$1.16	31.98

Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Evotec presently has a consensus target price of $3.00, indicating a potential upside of 55.44%. BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 15.43%. Given Evotec's stronger consensus rating and higher possible upside, equities analysts clearly believe Evotec is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

Summary

BioLife Solutions beats Evotec on 9 of the 15 factors compared between the two stocks.

How does Evotec compare to Maravai LifeSciences?

Evotec (NASDAQ:EVO) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Evotec currently has a consensus target price of $3.00, suggesting a potential upside of 55.44%. Maravai LifeSciences has a consensus target price of $6.25, suggesting a potential downside of 27.66%. Given Evotec's stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.8% of Evotec shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Evotec has a net margin of -26.20% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.70% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

In the previous week, Evotec had 7 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Evotec and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.19 beat Evotec's score of -0.13 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Evotec has higher revenue and earnings than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Maravai LifeSciences	$185.74M	12.08	-$130.77M	-$0.52	N/A

Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Summary

Evotec beats Maravai LifeSciences on 7 of the 13 factors compared between the two stocks.

How does Evotec compare to Azenta?

Evotec (NASDAQ:EVO) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Azenta has a net margin of -20.63% compared to Evotec's net margin of -26.20%. Azenta's return on equity of 1.18% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Azenta	-20.63%	1.18%	0.97%

Evotec currently has a consensus target price of $3.00, indicating a potential upside of 55.44%. Azenta has a consensus target price of $41.20, indicating a potential upside of 10.16%. Given Evotec's higher possible upside, equities research analysts clearly believe Evotec is more favorable than Azenta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Evotec had 8 more articles in the media than Azenta. MarketBeat recorded 10 mentions for Evotec and 2 mentions for Azenta. Azenta's average media sentiment score of 0.00 beat Evotec's score of -0.13 indicating that Azenta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market. Comparatively, Azenta has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Azenta has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A
Azenta	$593.82M	2.76	-$55.76M	-$2.76	N/A

5.8% of Evotec shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Azenta beats Evotec on 10 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$686.73M	$10.11B	$7.32B	$12.82B
Dividend Yield	N/A	1.46%	2.54%	10.78%
P/E Ratio	N/A	62.01	272.92	24.33
Price / Sales	0.77	109.40	635.93	97.39
Price / Cash	N/A	27.04	29.03	36.90
Price / Book	0.75	5.57	11.26	6.42
Net Income	-$117.12M	$56.67B	$3.47B	$348.89M
7 Day Performance	-1.53%	4.20%	2.35%	0.57%
1 Month Performance	-0.52%	11.38%	7.74%	4.90%
1 Year Performance	-46.98%	24.46%	25.22%	17.06%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	2.7045 of 5 stars	$1.93 flat	$3.00 +55.4%	-47.0%	$686.73M	$891.97M	N/A	4,553
ALMR Alamar Biosciences	1.0278 of 5 stars	$32.90 +17.5%	$31.80 -3.3%	N/A	$2.28B	$74.21M	N/A	222
FTRE Fortrea	2.4298 of 5 stars	$19.22 +1.2%	$20.75 +7.9%	+120.5%	$1.83B	$2.72B	N/A	14,300
BLFS BioLife Solutions	2.8228 of 5 stars	$34.90 +0.8%	$31.38 -10.1%	+43.2%	$1.70B	$96.21M	30.07	440	Positive News
MRVI Maravai LifeSciences	1.9329 of 5 stars	$6.05 -0.4%	$5.83 -3.5%	+252.7%	$1.56B	$185.74M	N/A	610	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. ALMR, FTRE, BLFS, MRVI, and AZTA

How does Evotec compare to Alamar Biosciences?

Summary

How does Evotec compare to Fortrea?

Summary

How does Evotec compare to BioLife Solutions?

Summary

How does Evotec compare to Maravai LifeSciences?

Summary

How does Evotec compare to Azenta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. ALMR, FTRE, BLFS, MRVI, and AZTA

How does Evotec compare to Alamar Biosciences?

Does the media refer more to EVO or ALMR?

Is EVO or ALMR more profitable?

Do analysts rate EVO or ALMR?

Do insiders & institutionals believe in EVO or ALMR?

Which has higher earnings & valuation, EVO or ALMR?

Summary

How does Evotec compare to Fortrea?

Does the media refer more to EVO or FTRE?

Do institutionals and insiders have more ownership in EVO or FTRE?

Which has more volatility and risk, EVO or FTRE?

Which has better earnings & valuation, EVO or FTRE?

Do analysts recommend EVO or FTRE?

Is EVO or FTRE more profitable?

Summary

How does Evotec compare to BioLife Solutions?

Do institutionals and insiders believe in EVO or BLFS?

Does the media favor EVO or BLFS?

Is EVO or BLFS more profitable?

Which has higher valuation and earnings, EVO or BLFS?

Which has more risk and volatility, EVO or BLFS?

Do analysts prefer EVO or BLFS?

Summary

How does Evotec compare to Maravai LifeSciences?

Do analysts prefer EVO or MRVI?

Do insiders & institutionals hold more shares of EVO or MRVI?

Is EVO or MRVI more profitable?

Does the media prefer EVO or MRVI?

Which has stronger earnings and valuation, EVO or MRVI?

Which has more volatility & risk, EVO or MRVI?

Summary

How does Evotec compare to Azenta?

Is EVO or AZTA more profitable?

Do analysts prefer EVO or AZTA?

Does the media favor EVO or AZTA?

Which has more risk & volatility, EVO or AZTA?

Which has higher valuation and earnings, EVO or AZTA?

Do institutionals and insiders believe in EVO or AZTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools